pharmjournalРазработка и регистрация лекарственных средствDrug development & registration2305-20662658-5049LLC «CPHA»10.33380/2305-2066-2019-8-2-16-21pharmjournal-676Research ArticleПОИСК И РАЗРАБОТКА НОВЫХ ЛЕКАРСТВЕННЫХ СРЕДСТВRESEARCH AND DEVELOPMENT OF NEW DRUG PRODUCTSИзучение десорбции и высвобождения терпено-индольных алкалоидов винкристина и винбластина из эритроцитарных клеточных носителейStudy of Desorbtion and Exemption of Terpeno-indole Alkaloids of Vinkristin and Vinblastin from Erythrocitary Cell CarriersТринееваО. В.TrineevaO. V.trineevaov@mail.ruХалахакунА. Д.KhalahakunA. D.ФГБОУ ВО «Воронежский государственный университет»РоссияVoronezh State UniversityRussian Federation201929052019821621Copyright © Тринеева О.В., Халахакун А.Д., 20192019Тринеева О.В., Халахакун А.Д.Trineeva O.V., Khalahakun A.D.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pharmjournal.ru/jour/article/view/676Введение

Введение. Сотрудниками кафедры фармацевтической химии и фармацевтической технологии были получены модифицированные формы известных в терапии онкологических заболеваний терпено-индольных алкалоидов (ТИА) – винкристина (VCR) и винбластина (VBL) путем их включения в эритроцитарные носители (ЭН) модифицированным методом гипоосмотического лизиса в модифицированной (апротонный растворитель – диметилсульфоксид (ДМСО) и полиэтиленгликоль (ПЭГ 4000) и немодифицированной средах.

Цель

Цель. Целью работы являлось изучение десорбции и высвобождения ТИА – VCR и VBL из ранее полученных клеточных ЭН.

Материалы и методы

Материалы и методы. В проведенном эксперименте определены характеристики высвобождения инкапсулированных препаратов из эритроцитов. Установлено, что в течение 6 ч in vitro высвобождается ТИА-препаратов из эритроцитарной формы: VCR – 54,5305%, VCR : ПЭГ-4000 (1:5) – 53,3305%, VCR : PEG-4000 (1:10) – 40,1283%, VCR : ПЭГ-4000 (1:20) – 39,9869%, VCR : ДМСО (2 мг/мл) – 54,2354%, VBL – 68,0656%; VBL : PEG-4000 (1:10) – 63,8941%; VBL : PEG-4000 (1:20) – 60,7455%; VBL : PEG-400 (1:20) – 60,3529%; VBL : ДМСО (2 мг/мл) – 64,5006%. Скорость высвобождения из эритроцитарной формы, инкапсулированной в среде, модифицированной ДМСО, значительно выше, чем инкапсулированных в немодифицированной среде. Средняя скорость высвобождения ТИА из эритроцитарных форм, инкапсулированных в среде ПЭГ приблизительно одинакова.

Результаты и обсуждение

Результаты и обсуждение. Полученные результаты показывают, что высвобождение гемоглобина из ТИА инкапсулированных эритроцитов по сравнению с неинкапсулированными ЭН невелико. Полученные результаты показывают, что из ТИА инкапсулированных ЭН, в среднем, высвобождается 8,242±0,3135% гемоглобина по сравнению с контрольными эритроцитами – 7,53% после 6 ч инкубирования при 37 °С. Выделения же гемоглобина из ТИА инкапсулированных эритроцитов в модифицированных средах меньше, чем инкапсулированных в немодифицированной среде.

Заключение

Заключение. На основе этих результатов можно сделать предложение, что ПЭГ может связываться с эритроцитарной мембраной и стабилизировать ее.

Introduction

Introduction. Employees of the Department of Pharmaceutical Chemistry and Pharmaceutical Technology have obtained modified forms of terpino-indole alkaloids (ТIA) and vinbristine (VCR) and vinblastine (VBL) known in the treatment of cancer diseases by incorporating them into the erythrocyte carriers (EN) by the modified method of hypoosmotic lysis in the modified (aprotic solvent dimethyl sulfoxide (DMSO) and polyethylene glycol (PEG 4000) and unmodified media.

Aim

Aim. The aim of the work was to study the desorption and release of terpene-indole vincristine and vinblastine alkaloids from previously obtained cellular erythrocyte carriers.

Materials and methods

Materials and methods. In the experiment performed, the release characteristics of encapsulated preparations from erythrocytes were determined. TIA preparations were released from erythrocyte form in 6 hours: VCR – 54.5305%, VCR : PEG-4000 (1:5) – 53.3305%, VCR : PEG-4000 (1:10) – 40.1283%, VCR : PEG-4000 (1:20) – 39.9869%, VCR : DMSO (2 mg/ml) – 54.2354%, VBL – 68.0656%; VBL : PEG-4000 (1:10) – 63.8941%; VBL : PEG-4000 (1:20) – 60.7455%; VBL : PEG-400 (1:20) – 60.3529%; VBL : DMSO (2 mg/ml) – 64.5006%. The rate of release from an erythrocyte form encapsulated in a medium modified with DMSO is significantly higher than that encapsulated in an unmodified medium. The average rate of TIA release from erythrocyte forms encapsulated in PEG medium is approximately the same.

Results and discussion

Results and discussion. The results show that the release of hemoglobin from TIA encapsulated erythrocytes compared with non-encapsulated EN is small. The results show that, on average, 8.242 ± 0.3135% of hemoglobin is released from TIA encapsulated with EN, compared to control erythrocytes – 7.53% after 6 h of incubation at 37 °C. The release of hemoglobin from the TIA of encapsulated erythrocytes in modified media is less than that encapsulated in unmodified medium.

Conclusion

Conclusion. Based on these results, it can be suggested that PEG can bind to the erythrocyte membrane and stabilize it.

винкристинвинбластинклеточные формы противоопухолевых препаратовадресные системы доставки лекарственных веществvincristinevinblastinecellular forms of antitumor drugstargeted drug delivery systemsReferencesТринеева О. В. и др. Морфологические и физико-химические свойства эритроцитарных носителей, инкапсулированных терпеноиндольными алкалоидами. Разработка и регистрация лекарственных средств. 2018; 1(22): 40–44.Trineeva O. V. et al. Morphological and physicochemical properties of erythrocyte carriers encapsulated with terpene-indole alkaloids. Drug development & registration. 2018; 1(22): 40–44 (In Russ.).Заборовский А. В., Гуревич К. Г. Моделирование направленного транспорта лекарственных веществ. Часть I. Однократное ведение. Сибирский онкологический журнал. 2017; 1(16): 59–65.Zaborovsky A. V., Gurevich K. G. Modeling of the directed transport of medicinal substances. Part I. Single management. Siberian Oncology Journal. 2017; 1(16): 59–65 (In Russ.).Заборовский А. В., Гуревич К. Г. Моделирование направленного транспорта лекарственных веществ. Часть II. Многократное введение. Сибирский онкологический журнал. 2017; 2(16): 36–41.Zaborovsky A. V., Gurevich K. G. Modeling of the directed transport of medicinal substances. Part II. Repeated introduction. Siberian Oncology Journal. 2017; 2(16): 36–41 (In Russ.).Ксейко Д. А., Генинг Т. П. Эффективность использования аутологичных клеток крови для адресной доставки в печень аскорбиновой кислоты с целью оптимизации коллоидно-осмотического давления крови после кровопотери. Ульяновский медико-биологический журнал. 2014; 2: 67–72.Kseiko D. A., Gening T. P. Efficiency of using autologous blood cells for targeted delivery of ascorbic acid to the liver in order to optimize the colloid osmotic pressure of blood after blood loss. Ulyanovsk Biomedical Journal. 2014; 2: 67–72 (In Russ.).Левин Г. Я., Соснина Л. Н. Использование ультрафиолетового облучения эритроцитов для увеличения их способности депонировать лекарственные препараты. Медицинский альмонах. 2013; 3(27): 67–69.Levin G. Ya., Sosnina L. N. The use of ultraviolet irradiation of erythrocytes to increase their ability to deposit drugs. Medical Almonas. 2013; 3(27): 67–69 (In Russ.).Левин Г. Я., Соснина Л. Н. Исследование реологических свойств эритроцитов, модифицированных для направленного транспорта лекарственных веществ. Фундаментальные исследования. 2013; 2(1): 105-109.Levin G. Ya., Sosnina L.N. Investigation of the rheological properties of erythrocytes modified for the directed transport of drugs. Basic research. 2013; 2(1): 105–109 (In Russ.).Ивонин А. Г. и др. Направленный транспорт лекарственных препаратов: современное состояние вопроса и перспективы. Известия Коми научного центра УрО РАН. 2012; 1 (9).Ivonin A.G. and others. Directed transport of drugs: current state of the issue and prospects. Proceedings of the Komi Scientific Center UB RAS. 2012; 1(9) (In Russ.).Banskota S. et al. Cell-Based Biohybrid Drug Delivery Systems: The Best of the Synthetic and Natural Worlds. 2017; 17(1).Banskota S. et al. Cell-Based Biohybrid Drug Delivery Systems: The Best of the Synthetic and Natural Worlds. 2017; 17(1).Bourgeaux V. et al. Drug-loaded erythrocytes: on the road toward marketing approval. Drug design, development and therapy. 2016; 10: 665–676.Bourgeaux V. et al. Drug-loaded erythrocytes: on the road toward marketing approval. Drug design, development and therapy. 2016; 10: 665–676.Coker S. A. et al. A Study of the Pharmacokinetic Properties and the In Vivo Kinetics of Erythrocytes Loaded With Dexamethasone Sodium Phosphate in Healthy Volunteers. Transfusion Medicine Reviews. 2017. https://doi.org/10.1016/j.tmrv.2017.09.001Coker S. A. et al. A Study of the Pharmacokinetic Properties and the In Vivo Kinetics of Erythrocytes Loaded With Dexamethasone Sodium Phosphate in Healthy Volunteers. Transfusion Medicine Reviews. 2017. DOI: https://doi.org/10.1016/j.tmrv.2017.09.001Deloach J. et al. Effect of glutaraldehyde treatment on enzyme-loaded erythrocytes. Biochimica et Biophysica Acta (BBA) – General Subjects. 1977; 496(2): 507–515.Deloach J. et al. Effect of glutaraldehyde treatment on enzyme-loaded erythrocytes. Biochimica et Biophysica Acta (BBA) – General Subjects. 1977; 496(2): 507–515.Sun Y. et al. Advances of blood cell-based drug delivery systems. European Journal of Pharmaceutical Sciences. 2017; 96: 115–128.Sun Y. et al. Advances of blood cell-based drug delivery systems. European Journal of Pharmaceutical Sciences. 2017; 96: 115–128.Zocchi E. et al. Encapsulation of doxorubicin in liver-targeted erythrocytes increases the therapeutic index of the drug in a murine metastatic model. Proceedings of the National Academy of Sciences of the United States of America. 1989; 86(6): 2040–2044.Zocchi E. et al. Encapsulation of doxorubicin in liver-targeted erythrocytes increases the therapeutic index of the drug in a murine metastatic model. Proceedings of the National Academy of Sciences of the United States of America. 1989; 86(6): 2040–2044.Rossi L. et al. Engineering erythrocytes for the modulation of drugs’ and contrasting agents’ pharmacokinetics and biodistribution. Advanced Drug Delivery Reviews. 2016; 106: 73–87.Rossi L. et al. Engineering erythrocytes for the modulation of drugs’ and contrasting agents’ pharmacokinetics and biodistribution. Advanced Drug Delivery Reviews. 2016; 106: 73–87.Villa C. H. et al. Erythrocytes as Carriers for Drug Delivery in Blood Transfusion and Beyond. Transfusion Medicine Reviews. 2017; 31(1): 26–35.Villa C. H. et al. Erythrocytes as Carriers for Drug Delivery in Blood Transfusion and Beyond. Transfusion Medicine Reviews. 2017; 31(1): 26–35.Kravtzoff R. et al. Erythrocytes as carriers for L-asparaginase. Methodological and mouse in-vivo studies. The Journal of pharmacy and pharmacology. 1990; 42(7): 473–476.Kravtzoff R. et al. Erythrocytes as carriers for L-asparaginase. Methodological and mouse in-vivo studies. The Journal of pharmacy and pharmacology. 1990; 42(7): 473–476.Field W. N. et al. A comparison of the treatment of thyroidectomized rats with free thyroxine and thyroxine encapsulated in erythrocytes. International Journal of Pharmaceutics. 1989; 51(2): 175–178.Field W. N. et al. A comparison of the treatment of thyroidectomized rats with free thyroxine and thyroxine encapsulated in erythrocytes. International Journal of Pharmaceutics. 1989; 51(2): 175–178.Harisa G.E. et al. Characterization of human erythrocytes as potential carrier for pravastatin: An in vitro study. International Journal of Medical Sciences. 2011; 8(3): 222–230.Harisa G.E. et al. Characterization of human erythrocytes as potential carrier for pravastatin: An in vitro study. International Journal of Medical Sciences. 2011; 8(3): 222–230.Hu C. M. J. et al. Erythrocyte-inspired delivery systems. Advanced Healthcare Materials. 2012; 1(5): 537–547.Hu C. M. J. et al. Erythrocyte-inspired delivery systems. Advanced Healthcare Materials. 2012; 1(5): 537–547.Favretto M.E. et al. Human erythrocytes as drug carriers: Loading efficiency and side effects of hypotonic dialysis, chlorpromazine treatment and fusion with liposomes. Journal of Controlled Release. 2013; 170(3): 343–351.Favretto M.E. [et al.] Human erythrocytes as drug carriers: Loading efficiency and side effects of hypotonic dialysis, chlorpromazine treatment and fusion with liposomes. Journal of Controlled Release. 2013; 170(3): 343–351.Ihler G. M. Tsang H. C. Hypotonic hemolysis methods for entrapment of agents in resealed erythrocytes. Methods in enzymology. 1987; 149: 221–229.Ihler G. M. Tsang H. C. Hypotonic hemolysis methods for entrapment of agents in resealed erythrocytes. Methods in enzymology. 1987; 149: 221–229.Magnani M. et al. Erythrocyte Engineering for Drug Delivery and Targeting. Texas. Eurekah.com. 2002; 151.Magnani M. et al. Erythrocyte Engineering for Drug Delivery and Targeting. Texas. Eurekah.com. 2002; 151.Magnani M., DeLoach J. R. The Use of Resealed Erythrocytes as Carriers and Bioreactors: Advances in Experimental Medicine and Biology. Boston. Springer US. 1992; 341.Magnani M., DeLoach J. R. The Use of Resealed Erythrocytes as Carriers and Bioreactors: Advances in Experimental Medicine and Biology. Boston. Springer US. 1992; 341.Skorokhod O. A. et al. Pharmacokinetics of erythrocyte-bound daunorubicin in patients with acute leukemia. Medical science monitor: international medical journal of experimental and clinical research. 2004; 10(4): 155–164.Skorokhod O. A. et al. Pharmacokinetics of erythrocyte-bound daunorubicin in patients with acute leukemia. Medical science monitor: international medical journal of experimental and clinical research. 2004; 10(4): 155–164.Bhimavarapu R. et al. Resealed erythrocytes as a targeted drug delivery system – an overview. PHARMANEST An International Journal of Advances in Pharmaceutical Sciences. 2012; 3(1): 47–64.Bhimavarapu R. et al. Resealed erythrocytes as a targeted drug delivery system – an overview. PHARMANEST An International Journal of Advances in Pharmaceutical Sciences. 2012; 3(1): 47–64.Wu Y. W. et al. Smart blood cell and microvesicle-based Trojan horse drug delivery: Merging expertise in blood transfusion and biomedical engineering in the field of nanomedicine. Transfusion and Apheresis Science. 2016; 54(2): 309–318.Wu Y. W. et al. Smart blood cell and microvesicle-based Trojan horse drug delivery: Merging expertise in blood transfusion and biomedical engineering in the field of nanomedicine. Transfusion and Apheresis Science. 2016; 54(2): 309–318.Sprandel U. et al. Erythrocytes as Drug Carriers in Medicine. Boston, MA: Springer US. 1997; 149.Sprandel U. et al. Erythrocytes as Drug Carriers in Medicine. Boston, MA: Springer US. 1997; 149.Sprandel U., Zöllner N. Osmotic fragility of drug carrier erythrocytes. Research in Experimental Medicine. 1985; 185(1): 77–85.Sprandel U., Zöllner N. Osmotic fragility of drug carrier erythrocytes. Research in Experimental Medicine. 1985; 185(1): 77–85.Thorpe S. R. et al. Enzyme Therapy. V. In Vivo Fate of Erythrocyteentrapped β-Glucuronidase in β-Glucuronidase-deficient mice. Pediatric Research. 1975; 9(12): 918–923.Thorpe S. R. et al. Enzyme Therapy. V. In Vivo Fate of Erythrocyteentrapped β-Glucuronidase in β-Glucuronidase-deficient mice. Pediatric Research. 1975; 9(12): 918–923.Tuhin F. T. et al. Essentials of Single-Cell Analysis: Series in BioEngineering. Berlin, Heidelberg: Springer Berlin Heidelberg. 2016; 325–346.Tuhin F. T. et al. Essentials of Single-Cell Analysis: Series in BioEngineering. Berlin, Heidelberg: Springer Berlin Heidelberg. 2016; 325–346.Updike S. et al. Asparaginase entrapped in red blood cells: action and survival. Science. 1976; 193(4254): 681–683.Updike S. et al. Asparaginase entrapped in red blood cells: action and survival. Science. 1976; 193(4254): 681–683.Халахакун А.Д. Получение и стандартизация эритроцитарных носителей, инкапсулированных терпеноиндольными алкалоидными противоопухолевыми препаратами: автореф. дис. канд. фарм. н. Москва. 2018; 26.Halakhakun A.D. Production and standardization of erythrocyte carriers encapsulated with terpene-indole alkaloid antineoplastic drugs: Sc.D. Moscow. 2018; 26.

The authors declare that there are no conflicts of interest present.